<DOC>
	<DOCNO>NCT01507480</DOCNO>
	<brief_summary>Antiangiogenic drug , bevacizumab , new treatment strategy Hereditary Hemorrhagic Telangiectasia ( HHT ) . Its systemic administration patient HHT improve liver damage-related symptom epistaxis ( case report on-going study-ClinicalTrials.gov Identifier # NCT00843440- ) . To limit systemic adverse effect bevacizumab ease administration , local administration seem suitable . A clinical case recently show benefit bevacizumab nasal spray patient . Its result confirm characterization study bevacizumab transport porcine nasal mucosa ( press ) . It seem necessary ass tolerance efficacy bevacizumab nasal spray human treatment epistaxis HHT prospective phase 1 study . The primary objective study evaluate tolerance increase dos bevacizumab administer nasal spray patient HHT-related epistaxis . This phase-1 , randomize , double-blind , placebo-controlled , monocentric study carry sequentially ( dose escalation ) 5 group 8 patient . Each group make 6 verum 2 placebo .</brief_summary>
	<brief_title>The ELLIPSE Study : A Phase-1 Study Evaluating Tolerance Bevacizumab Nasal Spray Treat Epistaxis Hereditary Hemorrhagic Telangiectasia</brief_title>
	<detailed_description />
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Epistaxis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age ≥ 18 year . Patients give voluntary , informed consent sign consent form . Patients affiliate French universal health care system . Patients treat HHT , confirm clinically ( presence lease 3 Curaçao criterion ) and/or molecular biology . Patients fill epistaxis tally sheet completely three month inclusion . Patients present severe epistaxis average 30 minute three month inclusion ( ( duration M1 + duration M2 + duration M3 ) / 3 ) . Patients whose number red blood cell transfusion six month inclusion know . Patients undergone nasal surgery three month inclusion . Pregnant woman woman could become pregnant study . Patients affiliate French universal health care system . Patients protect adult accord term law ( French public health law ) . Refusal give consent . Patients whose HHT diagnosis confirm clinically and/or molecular biology . Infectious episode . Patients present unchecked hypertension time inclusion ( systolic BP &gt; 150 mmHg and/or diastolic BP &gt; 100 mmHg ) without treatment . Patients hypertension include , blood pressure level control appropriate medical treatment . Participation another therapeutic trial 28 day inclusion . Patients already treat bevacizumab intravenous infusion . A known hypersensitivity active substance one excipients.A know hypersensitivity product contain Chinese hamster ovarian ( CHO ) cell human humanize recombinant antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Hemorrhagic Hereditary Telangiectasia ( HHT )</keyword>
	<keyword>Antiangiogenic therapy</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>